Alpha RegistryClaim a profile
Published mark

ASCENTAGE PHARMA GROUP INTERNATIONAL

NASDAQ: AAPG. Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:06c6c502-59c7-4d92-bd02-81b970584888
SEC CIK
0002023311
Record version
vpublic-1:ro-d751713988987e9331980363e24189ce, published Oct 21, 2026
Newest evidence
Apr 29, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Dajun Yang, M.D., Ph.D.Chairman, Chief Executive Officer and Director
Chair
Dajun Yang, M.D., Ph.D.
Independent
Not published
Published claims
192 distinct sources
Evidence records
20 pinned
Source conflicts
0None open

Built from 2 distinct sources and 2 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Chairman, Chief Executive Officer and DirectorDajun Yang, M.D., Ph.D.Not capturedunknownSource reportedE2
SVP, General CounselThomas J. KnappNot capturedunknownSource reportedE2
Chief Financial OfficerVeet Misra, Ph.D.Not capturedunknownSource reportedE2
Chief Medical OfficerYifan Zhai, M.D., Ph.D.Not capturedunknownSource reportedE2

Board of directors

Evidence
DirectorStatusSinceCommitteesClaim
Changqing YeIndependence not publishedNot publishedNone publishedSource reportedE2
Dajun Yang, M.D., Ph.D.Not independentChairNot publishedChief Executive Officer and Director, chairSource reportedE2
David Sidransky, M.D.Independence not publishedNot publishedNone publishedSource reportedE2
Debra YuIndependence not publishedNot publishedNone publishedSource reportedE2
Marc E. Lippman, M.D.Independence not publishedNot publishedNone publishedSource reportedE2
Marina S. BozilenkoIndependence not publishedNot publishedNone publishedSource reportedE2
Shaomeng Wang, Ph.D.Independence not publishedNot publishedNone publishedSource reportedE2
Simon Dazhong Lu, Ph.D.Independence not publishedNot publishedNone publishedSource reportedE2
Wei RenIndependence not publishedNot publishedNone publishedSource reportedE2

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
Chief Executive Officer and DirectorDajun Yang, M.D., Ph.D.Dajun Yang, M.D., Ph.D.Not described in the published record

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerDajun Yang, M.D., Ph.D., Chairman, Chief Executive Officer and Director
Source reportedE2
company:06c6c502-59c7-4d92-bd02-81b970584888:leadership_role:16
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingAAPG (NASDAQ)
Source reportedE1
company:06c6c502-59c7-4d92-bd02-81b970584888:security_listing:20
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 21, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameASCENTAGE PHARMA GROUP INTERNATIONAL
Source reportedE1
company:06c6c502-59c7-4d92-bd02-81b970584888:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:06c6c502-59c7-4d92-bd02-81b970584888:entity_status:3
Published FactHealthcare
Source reportedE1
company:06c6c502-59c7-4d92-bd02-81b970584888:published_fact:5
Published FactBiotechnology
Source reportedE1
company:06c6c502-59c7-4d92-bd02-81b970584888:published_fact:6

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • EventsInsufficient evidence. Governance events are derived from temporal changes in governed records.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
2 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 21, 2026. Cited by 6 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    SEC 20-F 0001213900-26-049412
    sec 20f. Published Apr 29, 2026. Retrieved Sep 5, 2026. Cited by 13 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

Version history

vpublic-1:ro-d751713988987e9331980363e24189ce published Oct 21, 2026

No published record changes are available in this projection.

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership4
  4. Board9
  5. Committees1
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims5
  15. Coverage gaps18
  16. Linked people12
  17. Subject and corrections6
  18. Evidence2
  19. Version historyvpublic-1:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:06c6c502-59c7-4d92-bd02-81b970584888
  • Cite this recordASCENTAGE PHARMA GROUP INTERNATIONAL
  • Copy canonical URLregistry.alpha.ac/companies/ascentage-pharma-group-international
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    ASCENTAGE PHARMA GROUP INTERNATIONALCompany
  • Dajun Yang, M.D., Ph.D.Person
  • Thomas J. KnappPerson
  • Veet Misra, Ph.D.Person
  • Yifan Zhai, M.D., Ph.D.Person
  • Changqing YePerson
  • David Sidransky, M.D.Person
  • Debra YuPerson
  • Marc E. Lippman, M.D.Person
  • Marina S. BozilenkoPerson
  • Shaomeng Wang, Ph.D.Person
  • Simon Dazhong Lu, Ph.D.Person
  • Wei RenPerson
  • Sections
    OverviewASCENTAGE PHARMA GROUP INTERNATIONAL
  • MonitoringASCENTAGE PHARMA GROUP INTERNATIONAL
  • LeadershipASCENTAGE PHARMA GROUP INTERNATIONAL
  • BoardASCENTAGE PHARMA GROUP INTERNATIONAL
  • CommitteesASCENTAGE PHARMA GROUP INTERNATIONAL
  • Control and votingASCENTAGE PHARMA GROUP INTERNATIONAL
  • Authority to actASCENTAGE PHARMA GROUP INTERNATIONAL
  • FinancialsASCENTAGE PHARMA GROUP INTERNATIONAL
  • GovernanceASCENTAGE PHARMA GROUP INTERNATIONAL
  • RiskASCENTAGE PHARMA GROUP INTERNATIONAL
  • AI oversightASCENTAGE PHARMA GROUP INTERNATIONAL
  • LegalASCENTAGE PHARMA GROUP INTERNATIONAL
  • CompensationASCENTAGE PHARMA GROUP INTERNATIONAL
  • Other published claimsASCENTAGE PHARMA GROUP INTERNATIONAL
  • Coverage gapsASCENTAGE PHARMA GROUP INTERNATIONAL
  • Linked peopleASCENTAGE PHARMA GROUP INTERNATIONAL
  • Subject and correctionsASCENTAGE PHARMA GROUP INTERNATIONAL
  • EvidenceASCENTAGE PHARMA GROUP INTERNATIONAL
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.